Science Explorer Back to mapMap
Discussion
Researcher · BC Cancer Agency · Canada

Laurie Helen Sehn

Laurie Helen Sehn publishes mostly in Pathology and Forensic Medicine, Oncology and Genetics, on topics such as Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and CAR-T cell therapy research.

ORCID 0000-0003-1860-9765 OpenAlex
World rank
#123,068
of 7,710,434 ranked researchers
Rank in Canada
#3,977
of 183,316
Works
655
Citations
31k
Citations per work
48.0
h-index
85
i10-index 282Top 0.8% in Pathology and Forensic Medicine
Laurie Helen Sehn

What does Laurie Helen Sehn research?

Laurie Helen Sehn's work is mostly in Medicine (74%), Immunology and Microbiology (4%).

Health Sciences: 485 works · 74.1% of their workMedicine: 485 works · 74.1% of their workPathology and Forensic Medicine: 207 works · 31.6% of their workOncology: 117 works · 17.9% of their workGenetics: 83 works · 12.7% of their workNeurology: 44 works · 6.7% of their workRadiology, Nuclear Medicine and Imaging: 34 works · 5.2% of their workEverything else: 143 works · 21.9% of their workLife Sciences: 26 works · 4.0% of their workImmunology and Microbiology: 26 works · 4.0% of their workImmunology: 26 works · 4.0% of their workTHEIR WORKLaurie Helen Sehn655works
Life Sciences4%Health Sciences74%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine48574.1%
  2. Everything else14321.9%
    1. Immunology and Microbiology264.0%
  1. 1Pathology and Forensic Medicine32% of their works
  2. 2Oncology18% of their works
  3. 3Genetics13% of their works
  4. 4Neurology7% of their works
  5. 5Radiology, Nuclear Medicine and Imaging5% of their works
  6. 6Immunology4% of their works

Research topics

Which keywords describe Laurie Helen Sehn's research?

The keywords of their largest research topics: Rituximab, Lymphoma, Classification, Molecular Profiling, Prognostic Factors, Chronic Lymphocytic Leukemia, Genomic Aberrations and CAR T Cells.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 19 words, with their numbers
  1. Rituximab7362 topics
  2. Lymphoma6462 topics
  3. Classification5251 topic
  4. Molecular Profiling5251 topic
  5. Prognostic Factors2532 topics
  6. Chronic Lymphocytic Leukemia2111 topic
  7. Genomic Aberrations2111 topic
  8. CAR T Cells1211 topic
  9. Chimeric Antigen Receptor1211 topic
  10. Primary CNS Lymphoma1121 topic
  11. Prognostic Scoring System1121 topic
  12. Epstein-Barr Virus991 topic
  13. Kaposi's Sarcoma991 topic
  14. Fc Receptors611 topic
  15. Therapeutic Antibodies611 topic
  16. EGFR Mutations441 topic
  17. Targeted Therapy441 topic
  18. Cutaneous Lymphomas421 topic
  19. Mycosis Fungoides421 topic

Where does Laurie Helen Sehn work?

Laurie Helen Sehn's main affiliation in the publication record is BC Cancer Agency, Canada.

How many publications and citations does Laurie Helen Sehn have?

OpenAlex counts 655 works and 31,448 citations for Laurie Helen Sehn, an h-index of 85, ranking #123,068 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Laurie Helen Sehn. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.